VSY Biotechnology GmbH Honored As 2021 MDEA Finalist

VSY Biotechnology GmbH Honored As 2021 MDEA Finalist

April 21, 2021

The 2021 Medical Design Excellence Awards Finalists have been announced! VSY Biotechnology is excited to share that VSY Biotechnology’s Trifocal IOL with Sinusoidal Vision Technology: Acriva Trinova is listed among the finalists of the Medical Design Excellence Awards competition.

Leinfelden – Echterdingen, Germany April 21, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics,announced today Acriva Trinova has been chosen as finalist in the Implant and Tissue-Replacement Productscategory of the 2021 Medical Design Excellence Awards (MDEA) competition.

The MDEA is the medical technology industry’s premier awards program. Since 1998, the MDEAs have recognized achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.

“We are so thrilled to be nominated as MDEA finalist. We keep focusing on our aim to produce innovative products to make our doctors’ and patients’ lives better with our strong R&D projects as well as manufacturing capacity”, said Fatih Ergin, CEO.

Acriva Trinova is a trifocal intraocular lens (IOL) designed with patented “Sinusoidal Vision Technology (SVT)”. Its smoothly undulating surface profile provides the highest light transmission, optimum light distribution for patients at near, intermediate, and far distances. Because of minimized light, scatter, and balanced light distribution halo/glare effects are much reduced.

The winners will be announced on Thursday, May 13, during the Medtech Design Summit. Vote for your choice for the 2021 MD+DI Readers’ Choice Winners here: Vote!